Association between Serum Liver Enzymes and Metabolic Syndrome in Korean Adults
by
Hae Ran Kim 1 and
Mi Ah Han 2,*
Hae Ran Kim 1 and
Mi Ah Han 2,*
1
Department of Nursing, School of Medicine, Chosun University, Gwangju 61452, Korea
2
Department of Preventive Medicine, School of Medicine, Chosun University, Gwangju 61452, Korea
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2018, 15(8), 1658; https://doi.org/10.3390/ijerph15081658
Received: 28 June 2018 / Revised: 26 July 2018 / Accepted: 2 August 2018 / Published: 5 August 2018
The purpose of this study was to evaluate the association between alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and metabolic syndrome (MS) in the Korean population. A total of 11,587 adults ≥30 years of age and with complete data were selected from Korea National Health and Nutrition Examination Survey VI conducted from 2013 to 2015. Normal ALT and AST levels were divided into quartiles, and their associations with MS were assessed by logistic regression analysis. Elevated levels of ALT [adjusted odds ratio (aOR) = 7.90, 95% confidence interval (CI) = 6.50–9.60] and AST (aOR = 3.81, 95% CI = 3.10–4.74) were both significantly associated with a higher prevalence of MS. The quartile group containing the highest levels of ALT and AST within the normal range also showed an increased risk of MS and its components. Elevated levels of ALT and AST, even within the normal range, were associated with prevalence of MS.
View Full-Text
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Kim, H.R.; Han, M.A. Association between Serum Liver Enzymes and Metabolic Syndrome in Korean Adults. Int. J. Environ. Res. Public Health 2018, 15, 1658.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
